Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03049618 | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04215978 | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 204 | BeiGeneINDUSTRY | 8 | Oct 3, 2025 | clinicaltrials |
| NCT01644786 |
| The Head and Neck Tumor Biobank |
| completed |
| — |
| 419 |
| Maastricht Radiation OncologyOTHER |
| 1 |
| Oct 2, 2025 |
| clinicaltrials |
| NCT04260126 | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC(VERSATILE002) | completed | Phase 2 | 95 | PDS Biotechnology Corp.INDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT05271604 | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 42 | BioAtla, Inc.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT04417465 | First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors | completed | Phase 1 | 101 | AbbVieINDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT05459129 | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | completed | Phase 1 / Phase 2 | 12 | Hoffmann-La RocheINDUSTRY | 3 | Sep 15, 2025 | clinicaltrials |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | completed | Phase 1 | 89 | Tempest TherapeuticsINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04694846 | Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use | completed | N/A | 19 | Thomas Jefferson UniversityOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06771674 | Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma | completed | — | 662 | Hookipa Biotech GmbHINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04879849 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | completed | Phase 1 | 34 | TakedaINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03552965 | Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC | completed | N/A | 23 | University of ArkansasOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05323656 | A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | completed | Phase 2 | 55 | Calliditas Therapeutics Suisse SAINDUSTRY | 7 | Sep 2, 2025 | clinicaltrials |
| NCT06272513 | Influencing Factors for Physical Activity in People With Head and Neck Cancer(ProAct-HNC) | completed | — | 20 | Kantonsspital Winterthur KSWOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT06273852 | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | completed | Early Phase 1 | 8 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03623646 | Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.(CITHARE) | completed | Phase 2 | 11 | Institut Claudius RegaudOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | completed | Phase 1 | 60 | Xencor, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05156970 | Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC | completed | Phase 2 | 81 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT03795610 | IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 16 | Assuntina G. Sacco, MDOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT03635164 | Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma | completed | Phase 1 | 21 | University of Colorado, DenverOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06112535 | Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery | completed | N/A | 60 | CMR Surgical LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04489888 | A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) | completed | Phase 4 | 101 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Jun 19, 2025 | clinicaltrials |
| NCT07015333 | Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab | completed | — | 31 | Commonwealth Healthcare CorporationOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04616196 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | completed | Phase 1 / Phase 2 | 25 | Nektar TherapeuticsINDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT03317327 | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors(REPORT) | completed | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05499065 | Real-time Margin Assessment in Head and Neck Cancer(LIGHTNING) | completed | Phase 2 | 23 | University Medical Center GroningenOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06757530 | Radiomics Model for Assessing Lymph Node Status in cN0 Patients withHNSCC | completed | — | 700 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT03953443 | Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC | completed | — | 25 | New Mexico Cancer Research AllianceOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT05516589 | Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC(neoCHANCE-2) | completed | Phase 2 | 40 | West China HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT04121286 | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China | completed | Phase 1 | 17 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT04555837 | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | completed | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT02245100 | Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer | completed | — | 130 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02318771 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | completed | Phase 1 | 41 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03618654 | Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma | completed | Early Phase 1 | 38 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03524326 | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT03944915 | De-Escalation Therapy for Human Papillomavirus Negative Disease(DEPEND) | completed | Phase 2 | 35 | University of ChicagoOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT03212469 | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer(ABIMMUNE) | completed | Phase 1 / Phase 2 | 54 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT04278092 | Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure | completed | Phase 2 | 57 | Medical University of ViennaOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT03107182 | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer(OPTIMA-II) | completed | Phase 2 | 72 | University of ChicagoOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT03342911 | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | completed | Phase 2 | 34 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04752384 | Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients | completed | Phase 2 | 20 | Medical College of WisconsinOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT04830592 | A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck(MOAT) | completed | Phase 1 | 36 | Akamis BioINDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT03602911 | A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients | completed | Phase 2 | 20 | West Virginia UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06865313 | Functional Evaluation After Maxillectomy and Scapular Free Flap Reconstruction | completed | — | 16 | Hôpital de la Croix-RousseOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03721757 | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer(NICO) | completed | Phase 2 | 21 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04091867 | sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC | completed | Phase 1 | 3 | University of Colorado, DenverOTHER | 1 | Feb 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 22, 2025source: clinicaltrials